about
CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cellsCD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activationHuman spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoproteinCDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosisProtein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signalingSignal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin.The dual-function CD150 receptor subfamily: the viral attraction.Expression of CD150 in tumors of the central nervous system: identification of a novel isoform.Measles virus hemagglutinin triggers intracellular signaling in CD150-expressing dendritic cells and inhibits immune response.Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.The multilevel regulation of CD95 signaling outcome.Early B-cell factor 1 (EBF1) is critical for transcriptional control of SLAMF1 gene in human B cells.Differential expression of CD150/SLAMF1 in normal and malignant B cells on the different stages of maturation.Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. I. Cell surface phenotype and functional studies.The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines.Epidermoid carcinoma-derived antimicrobial peptide (ECAP) inhibits phosphorylation by protein kinases in vitro.Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules.FCRL6 receptor: expression and associated proteins.Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes.The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.[Current theories on the origin of Reed-Sternberg cells in lymphogranulomatosis][IPO-10 monoclonal antibodies to the human B-lymphocyte differentiation antigen]The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells.[Determination of subpopulations of normal and malignant transformed lymphocytes in blood smears by an immunoenzyme histochemical method using monoclonal antibodies][Monoclonal antibodies to RPMI-1788 lymphoblastoid line cells]Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and transcription factors expression profile.Regulation of lymphocyte activation by the cell-surface molecule CD22Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomasDominant nature of the resistance to Fas- and tumor necrosis factor-alpha-mediated apoptosis in human prostatic carcinoma cell lines[Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases][Monoclonal antibodies IPO-4 recognizing antigen-activated human T and B lymphocytes][The expression of an antigen interacting with monoclonal antibody IB4 on the surface membranes of normal human leukocytes and in lymphoproliferative diseases][Morphocytochemical and electron microscopic research on murine hybridoma cells producing and not producing monoclonal antibodies]Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens[Ultrastructural organization of the blood lymphoid cells in hairy cell leukemia][Cytochemical studies of T- and B-lymphocyte subpopulations in normal conditions and in malignant lymphoproliferative diseases]SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?
P50
Q24303493-3944D7A6-4CEE-4927-877C-177CA11E4FFFQ24310493-7BE7B506-674B-4D4F-9B06-1B98D80106E0Q24562809-BAC49A2E-1E58-41AF-B1CF-B5C411E2A4F3Q28143082-025EF417-2F42-4FBC-85CB-9671C68D8851Q28294447-18217C22-2BE7-4730-94CC-F4ADC8E6E5BBQ33208079-57F731F3-4B23-4563-8820-F0260F6EA17BQ35032536-E555858A-B96F-4208-AE3A-62AB40808C60Q35566887-9BF52DA5-99D1-4E34-BB73-70FD1B482D40Q37402444-52EA2DE0-1B99-47E7-8BA0-4F2CBD8C769DQ37832638-FC68A4C2-7D8F-47C3-B5C0-42C3E5B95D0BQ38052379-B4F6769B-AA4D-40D7-B99F-92AC98B58F90Q38757738-07CA5BAD-C5F8-44A9-8F89-64E9AAECC4DEQ38760956-B2B75C73-3F7A-4B39-999D-9866B0E18120Q39009337-D1A33B1D-6551-4296-9917-C05033F803B7Q40438426-F9001ECC-FE52-4B11-AAD4-C488C37E68AEQ40762975-0FB9EE17-ABA6-4723-980D-7DA05CAAE4DEQ41332122-810CA8AE-1E6C-49F7-B804-9C4B24E465F6Q41412768-E34A3D3D-2F5C-4598-94F2-8D1966AEE9D4Q41515327-13EBAB66-EBFB-4324-90C9-A5FC82C48700Q42370806-ECA82B97-6D61-48BB-A64F-5F5212D7B8F9Q43939721-AEE6D2DF-FE57-4259-8D60-B2838AB7C512Q44211306-D9CB259A-96C9-45EA-ACAD-DF2D43C5B907Q45021703-AF2D627A-E570-4AC5-B6E1-1D006FF47A18Q53524304-B4751FB9-E431-46AE-8C33-02279BBBEAFCQ53540141-29A9BCA7-97C5-410D-9AEC-9E00F541FC37Q54190429-4AF51FC0-8C50-4324-965A-1332F74B43D2Q56964563-3EE24F0F-50C0-4FE1-906A-D51C8D7A3D7EQ60690450-C1496D8F-CC69-4952-819E-22BDEE94992BQ60690479-520D2695-6749-4397-AAAF-394BBA7332AAQ60690498-C993605D-A194-4D67-937E-B4E689488BDFQ60690500-355647E1-0946-4372-811A-52C5E2E1033AQ60690501-29AC8A93-9EBE-4C0E-9990-7046B2CACAF7Q60690506-E30956D9-8281-49E2-BE12-000A57904E0FQ60690509-3F8B08AF-F488-470F-880B-668D271EF219Q60690515-715438EE-B600-4C5E-A62E-0556E628C5E3Q60690516-444BA430-7630-4016-AC9F-577A692099B3Q90927686-B064AE08-E8F7-4D03-A541-93AE29011701
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Svetlana Sidorenko
@ast
Svetlana Sidorenko
@en
Svetlana Sidorenko
@es
Svetlana Sidorenko
@nl
Svetlana Sidorenko
@sl
type
label
Svetlana Sidorenko
@ast
Svetlana Sidorenko
@en
Svetlana Sidorenko
@es
Svetlana Sidorenko
@nl
Svetlana Sidorenko
@sl
altLabel
Svitlana Sydorenko
@en
prefLabel
Svetlana Sidorenko
@ast
Svetlana Sidorenko
@en
Svetlana Sidorenko
@es
Svetlana Sidorenko
@nl
Svetlana Sidorenko
@sl
P106
P1153
55400693000
P21
P31
P496
0000-0001-8281-8006